Business
VISITECT® CD4 commercialisation update
VISITECT® CD4 commercialisation update.
About this update from Cambridge Nutritional Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 9407U Omega Diagnostics Group PLC 18 July 2018 \n\n \nOmega Diagnostics Group PLC\n(\"Omega\" or \"the Company\")\n \nVISITECT® CD4 commercialisation update\n \nOmega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its VISITECT® CD4 commercialisation programme.\n \nThe Company announces the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe. This follows on from the appointment of their first dedicated distributor for CD4 in Nigeria. All three countries require product registration, which has also commenced. Once completed, this will allow business to business sales to commence through the Company's distributors. The three countries have a high prevalence of people living with HIV and have been priortised on that basis. \n \nColin King, CEO of Omega commented: \"I am pleased to see our commercialisation plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value. This also provides further evidence that our CD4 test (the world's first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments.\"\n \nThe information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \nContacts:\n \n\n\n\nOmega Diagnostics Group PLC \n\n\nTel: 01259 763 030\n\n\n\n\nColin King, Chief Executive \n\n\nwww.omegadiagnostics.com\n\n\n\n\nKieron Harbinson, Group Finance Director\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\nfinnCap Ltd &...